Ftse Mib
33.766,29
-0,06%
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
NASDAQ
19.572,60
1,03%
Bitcoin
97.523,31
-0,26%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Johnson and Johnson (JNJ) Johnson and Johnson (JNJ) Notizie

Johnson and Johnson

JNJ
144,70
1,12 (0,78%)
21 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NYSE
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
12/12/202423:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202423:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202423:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202422:30BWJohnson & Johnson to Participate in the 43rd Annual J.P...
10/12/202414:00BWJohnson & Johnson to Host Investor Conference Call on..
10/12/202401:30PRNUSCARVYKTI® (ciltacabtagene autoleucel) demonstrated..
09/12/202414:00PRNUSWarm autoimmune hemolytic anemia (wAIHA) research presented..
09/12/202401:30PRNUSDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based..
08/12/202418:33PRNUSTECVAYLI® (teclistamab-cqyv) demonstrates potential as..
08/12/202417:21PRNUSDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows..
04/12/202419:25EDGAR2Form 144 - Report of proposed sale of securities
02/12/202414:00PRNUSJohnson & Johnson seeks U.S. FDA approval for first..
22/11/202414:00PRNUSJohnson & Johnson seeks U.S. FDA approval for subcutaneous..
21/11/202422:00PRNCAHealth Canada Authorizes CARVYKTI® (ciltacabtagene..
19/11/202415:02PRNUSJohnson & Johnson to showcase strength of its broad..
18/11/202422:30PRNUSIcotrokinra delivered an industry-leading combination of..
14/11/202416:00PRNUSNipocalimab demonstrates significant clinical improvement in..
13/11/202422:45EDGAR2Form 13F-HR - Quarterly report filed by institutional..
11/11/202422:05PRNUSNipocalimab is the first and only investigational therapy..
08/11/202413:00PRNUSJohnson & Johnson submits applications in the U.S. and EU..
07/11/202414:00PRNUSJohnson & Johnson advances leadership in rheumatic disease..
06/11/202415:23EDGAR2Form 25-NSE - Notification filed by national security..
04/11/202421:11GLOBEEmpower 2024 Delivers Groundbreaking Insights and Innovation..
01/11/202416:05EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
28/10/202412:30PRNUSTREMFYA® (guselkumab) is the first and only IL-23 inhibitor..
25/10/202414:05PRNUSNew SPECTREM study findings reveal TREMFYA® (guselkumab)..
24/10/202414:00PRNUSJohnson & Johnson highlights innovative neuropsychiatry..
23/10/202422:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
22/10/202400:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/10/202423:23EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
18/10/202422:47EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
15/10/202422:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/10/202414:00PRNUSNipocalimab demonstrates sustained disease control in..
15/10/202413:37EDGAR2Form 8-K - Current report
15/10/202412:25BWJohnson & Johnson Announces Quarterly Dividend for Fourth..
15/10/202412:20BWJohnson & Johnson Reports Q3 2024 Results
15/10/202411:49IHMARKETNEWSU.S. Index Futures Mixed; Oil Prices Fall as Israel Eases..
14/10/202415:08IHMARKETNEWSInterest Rate Optimism May Lead To Continued Strength On..
11/10/202412:31IHMARKETNEWSBP Signals Rising Net Debt; Tesla Slumps; Stellantis CEO..
10/10/202422:30BWJohnson & Johnson to Participate in the Stifel 2024..
10/10/202414:00PRNUSTREMFYA® (guselkumab) demonstrates impressive results across..
09/10/202423:07EDGAR2Form 3 - Initial statement of beneficial ownership of..
09/10/202414:00BWJohnson & Johnson Completes Acquisition of V-Wave
04/10/202422:30BWJohnson & Johnson to Participate in the Guggenheim Global..
03/10/202414:45IHNWBeyond the Horizon: Innovative Drug Combinations Offer New..
02/10/202415:00PRNUSERLEADA® (apalutamide) demonstrates statistically..
30/9/202422:05PRNUSJohnson & Johnson files for U.S. FDA approval of DARZALEX..
30/9/202414:05PRNUSJohnson & Johnson Rolls Out New TECNIS Odyssey..
27/9/202422:30PRNUSCARVYKTI® is the first and only cell therapy to..
27/9/202419:05PRNUSDARZALEX® (daratumumab)-based maintenance regimens show..
Apertura: 143,55 Min: 143,48 Max: 145,47
Chiusura: 143,58

La tua Cronologia

NYSE
JNJ
Johnson and Johnson
BIT
UB26FZ
UniCredit Bank
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network